Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (291-300 of 345) with videos related to

Pageof 35
Sort By:
Annals of the Rheumatic Diseases|January 31, 2007
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsJohan Askling, C Michael Fored, Lena Brandt, et al.
Rheumatology (Oxford, England)|June 20, 2022
Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countriesBente Glintborg, Daniela Di Giuseppe, Johan K Wallman, et al.
Rheumatology (Oxford, England)|December 23, 2021
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registriesDaniela Di Giuseppe, Ulf Lindström, Kalle Aaltonen, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registriesBente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, et al.
Rheumatology (Oxford, England)|November 19, 2010
Ten years with biologics: to whom do data on effectiveness and safety apply?Julia F Simard, Elizabeth V Arkema, Anders Sundström, et al.
Clinical Epidemiology|January 20, 2021
Adaptation of the Charlson Comorbidity Index for Register-Based Research in SwedenJonas F Ludvigsson, Peter Appelros, Johan Askling, et al.
The Journal of Rheumatology|September 1, 2024
Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic RegistriesSella Aarrestad Provan, Lotta Ljung, Eirik Klami Kristianslund, et al.
Rheumatology (Oxford, England)|June 16, 2023
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritisAnton Öberg Sysojev, Saedis Saevarsdottir, Lina-Marcela Diaz-Gallo, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersLouise K Mercer, Johan Askling, Pauline Raaschou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 21, 2025
Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid ArthritisLinda Mathsson Alm, Helga Westerlind, Isabel Gehring, et al.
Pageof 35

Showing results (291-300 of 345) with videos related to

Sort By:
Pageof 35
Annals of the Rheumatic Diseases|January 31, 2007
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonistsJohan Askling, C Michael Fored, Lena Brandt, et al.
Rheumatology (Oxford, England)|June 20, 2022
Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countriesBente Glintborg, Daniela Di Giuseppe, Johan K Wallman, et al.
Rheumatology (Oxford, England)|December 23, 2021
The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registriesDaniela Di Giuseppe, Ulf Lindström, Kalle Aaltonen, et al.
Annals of the Rheumatic Diseases|February 22, 2023
Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registriesBente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, et al.
Rheumatology (Oxford, England)|November 19, 2010
Ten years with biologics: to whom do data on effectiveness and safety apply?Julia F Simard, Elizabeth V Arkema, Anders Sundström, et al.
Clinical Epidemiology|January 20, 2021
Adaptation of the Charlson Comorbidity Index for Register-Based Research in SwedenJonas F Ludvigsson, Peter Appelros, Johan Askling, et al.
The Journal of Rheumatology|September 1, 2024
Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic RegistriesSella Aarrestad Provan, Lotta Ljung, Eirik Klami Kristianslund, et al.
Rheumatology (Oxford, England)|June 16, 2023
Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritisAnton Öberg Sysojev, Saedis Saevarsdottir, Lina-Marcela Diaz-Gallo, et al.
Annals of the Rheumatic Diseases|June 17, 2016
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registersLouise K Mercer, Johan Askling, Pauline Raaschou, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 21, 2025
Recognition of Glycine Versus Nonglycine Citrulline Motifs Dictating the HLA Class II Association of Anticitrullinated Protein Antibodies: Insights From Autoantibody Profiling of 6,900 Scandinavian Patients With Rheumatoid ArthritisLinda Mathsson Alm, Helga Westerlind, Isabel Gehring, et al.
Pageof 35